Sunlight may increase the FDG uptake value in primary tumors of patients with non-small cell lung cancer

Oncology Letters

Volumn 5, Issue 3, 2013, Pages 773-776

  Mutlu, Hasan ^a   Büyükçelik, Abdullah ^b   Kaya, Eser ^a   Kibar, Mustafa ^c   Seyrek, Ertuǧrul ^c   Yavuz, Sinan ^b   Çalikuşu, Züleyha ^c  

^a Acibadem Kayseri Hospital   (Turkey)

^b ACIBADEM UNIVERSITY   (Turkey)

^c ADANA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Lung cancer; Maximal standardized uptake value; Positron emission tomography; Season

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER PROGNOSIS; CLIMATE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; SUNLIGHT;

EID: 84872724181     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1112     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Ries LAG, Eisner MP, Kosary CL, et al (eds): SEER Cancer Statistics Review, 1975-2002. National Cancer Institute, Bethesda, MD, 2005.
3. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706-714, 2007.
4. Caglar HB, Baldini EH, Othus M, et al: Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery. Cancer 115: 4156-4166, 2009.
5. Hoang T, Xu R, Schiller JH, Bonomi P and Johnson DH: Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 23: 175-183, 2005.
6. Blackstock AW, Herndon JE II, Paskett ED, Perry MC, et al: Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. Blackstock J Natl Cancer Inst 94: 284-290, 2002.
7. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al: Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg 63: 1441-1450, 1997.
8. No authors listed: Postoperative T1 N0 non-small cell lung cancer. Squamous versus nonsquamous recurrences. The Lung Cancer Study Group. J Thorac Cardiovasc Surg 94: 349-354, 1987.
9. Harpole DH Jr, Herndon JE II, Young WG Jr, Wolfe WG and Sabiston DC Jr: Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 76: 787-796, 1995.
10. Takise A, Kodama T, Shimosato Y, Watanabe S and Suemasu K: Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 61: 2083-2088, 1988.
11. Shields TW: Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of the lung. Surg Gynecol Obstet 157: 185-190, 1983.
12. Berghmans T, Paesmans M and Sculier JP: Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol 3: 127-138, 2011.
13. Barlési F, Doddoli C, Torre JP, et al: Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy. Eur J Cardiothorac Surg 28: 629-634, 2005.
14. Riquet M, Bagan P, Le Pimpec Barthes F, et al: Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg 84: 1818-1824, 2007.
15. Kameyama K, Huang CL, Liu D, et al: Problems related to TNM staging: patients with stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 124: 503-510, 2002.
16. Albain KS, Swann RS, Rusch VW, et al: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374: 379-386, 2009.
17. Niizeki H, Morikawa T, Okushiba S, Kondo S and Katoh H: Survival and prognostic factors in resected cN2-pN0 non-small cell lung cancer. Ann Thorac Cardiovasc Surg 10: 9-13, 2004.
18. Mitsudomi T, Hamajima N, Ogawa M and Takahashi T: Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6: 4055-4063, 2000.
19. Mascaux C, Iannino N, Martin B, et al: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92: 131-139, 2005.
20. Martin B, Paesmans M, Berghmans T, et al: Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 89: 55-64, 2003.
21. Berghmans T, Paesmans M, Mascaux C, et al: Thyroid transcription factor 1-a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol 17: 1673-1676, 2006.
22. Nakamura H, Kawasaki N, Taguchi M and Kabasawa K: Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 61: 140-145, 2006.
23. Meert AP, Martin B, Paesmans M, et al: The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 89: 959-965, 2003.
24. Zhan P, Wang J, Lv XJ, et al: Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 4: 1094-1103, 2009.
25. Paesmans M, Berghmans T, Dusart M, et al: Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 5: 612-619, 2010
26. De Wever W, Vankan Y, Stroobants S and Verschakelen J: Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J 29: 995-1002, 2007.
27. Antoch G, Stattaus J, Nemat AT, et al: Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229: 526-533, 2003.
28. Gámez C, Rosell R, Fernández A, et al: PET/CT fusion scan in lung cancer: current recommendations and innovations. J Thorac Oncol 1: 74-77, 2006.
29. Nair VS, Krupitskaya Y and Gould MK: Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol 4: 1473-1479, 2009.
30. Pöttgen C, Levegrün S, Theegarten D, et al: Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 12: 97-106, 2006.
31. Hoekstra CJ, Stroobants SG, Smit EF, et al: Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23: 8362-8370, 2005.
32. Zhu K, Bruce D, Austin N, Devine A, Ebeling PR and PrinceRL: Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. J Bone Miner Res 23: 1343-1348, 2008.
33. Beer TM and Myrthue A: Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther 3: 373-381, 2004.
34. Higashimoto Y, Ohata M, Nishio K, et al: 1 alpha, 25-dihydroxy vitamin D3 and all-trans-retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res 16: 2653-2659, 1996.
35. Wood AW, Chang RL, Huang MT, Uskokovic M and Cooney AH: 1α,25-dihydroxy vitamin D3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin. Biochem Biophys Res Commun 116: 605-611, 1983.
36. Ordonez-Moran P, Larriba MJ, Pendas-Franco N, Aguilera O, Gonzalez-Sancho JM and Munoz A: Vitamin D and cancer: an update of in vitro and in vivo data. Front Biosci 10: 2723-2749, 2005.
37. Hansen CM, Binderup L, Hamberg KJ and Carlberg C: Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci 6: 820-848, 2001.
38. Trump DL, Hershberger PA, Bernardi RJ, et al: Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol 89-90: 519-526, 2004.
39. Nakagawa K, Sasaki Y, Kato S, Kubodera N and Okano T: 22-Oxa-1a,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26: 1044-1054, 2005.
40. Young MR, Ihm J, Lozano Y, Wright MA and Prechel MM: Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence. Cancer Immunol Immunother 41: 37-45, 1995.
41. Kilkkinen A, Knekt P, Heliövaara M, et al: Vitamin D status and the risk of lung cancer: a cohort study in Finland. Cancer Epidemiol. Biomarkers Prev 17: 3274-3278, 2008.
42. Zhou W, Heist RS, Liu G, et al: Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev 14: 2303-2309, 2005.
43. Zhou W, Heist RS, Liu G, Asomaning K, et al: Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol 25: 479-485, 2007.
44. Lim HS, Roychoudhuri R, Peto J, Schwartz G, Baade P and Møller H: Cancer survival is dependent on season of diagnosis and sunlight exposure. Int J Cancer 119: 1530-1536, 2006.